Emerging Company Profile
Out of the Arena: With $56M round, spinout Longboard to house trio of neuroscience programs
Emerging Company Profile: Longboard has three programs that each share targets with existing Arena molecules
Longboard Pharmaceuticals raises its first cash from a syndicate led by Farallon Capital and spins out of Arena with three programs that each share a target with an existing molecule from the parent company.
Oct 28, 2020 | 11:25 PM GMT
With $56 million in fresh funding from a